Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction that occurs secondary to loss of dopaminergic neurons in the nigrostriatal pathway. Current pharmacotherapies focus on the replacement of lost dopamine to alleviate disease symptoms. However, over time this method of therapy loses effectiveness due to the continued death of dopaminergic neurons. Alternative strategies for the treatment of PD are aimed at modifying the disease state through the preservation of remaining dopamine neurons or even the regeneration of dopamine innervation through the use of neurotrophic factors. Neurotrophic factors are specialized proteins that can promote neuronal development, maintain neuronal health and modulate neuronal function in the ventral midbrain, making them candidates for the treatment of PD. Preclinial studies indicate that members of the glial cell line-derived neurotrophic factor family of ligands are capable of preserving the degenerating dopamine neurons. These promising results moved neurotrophic factor therapy to clinical trials in PD patients. To date, neurotrophic factor therapy is proven to be safe and well-tolerated in humans, but conclusive evidence of efficacy in the clinic remains to be determined. This review will discuss the preclinical and clinical experiments of glial cell line-derived neurotrophic factor family ligands for the treatment of PD.
Keywords: Gene therapy, Glial cell line-derived neurotrophic factor, glial cell line-derived neurotrophic factor family ligands, neurprotection, Neurotrophic factors, Neurturin, Parkinsons disease, Pars Compacta, L-DOPA, Neurorestoration, NRTN, MFB
CNS & Neurological Disorders - Drug Targets
Title: GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
Volume: 10 Issue: 6
Author(s): Amanda L. Mickiewicz and Jeffrey H. Kordower
Affiliation:
Keywords: Gene therapy, Glial cell line-derived neurotrophic factor, glial cell line-derived neurotrophic factor family ligands, neurprotection, Neurotrophic factors, Neurturin, Parkinsons disease, Pars Compacta, L-DOPA, Neurorestoration, NRTN, MFB
Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction that occurs secondary to loss of dopaminergic neurons in the nigrostriatal pathway. Current pharmacotherapies focus on the replacement of lost dopamine to alleviate disease symptoms. However, over time this method of therapy loses effectiveness due to the continued death of dopaminergic neurons. Alternative strategies for the treatment of PD are aimed at modifying the disease state through the preservation of remaining dopamine neurons or even the regeneration of dopamine innervation through the use of neurotrophic factors. Neurotrophic factors are specialized proteins that can promote neuronal development, maintain neuronal health and modulate neuronal function in the ventral midbrain, making them candidates for the treatment of PD. Preclinial studies indicate that members of the glial cell line-derived neurotrophic factor family of ligands are capable of preserving the degenerating dopamine neurons. These promising results moved neurotrophic factor therapy to clinical trials in PD patients. To date, neurotrophic factor therapy is proven to be safe and well-tolerated in humans, but conclusive evidence of efficacy in the clinic remains to be determined. This review will discuss the preclinical and clinical experiments of glial cell line-derived neurotrophic factor family ligands for the treatment of PD.
Export Options
About this article
Cite this article as:
L. Mickiewicz Amanda and H. Kordower Jeffrey, GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy, CNS & Neurological Disorders - Drug Targets 2011; 10 (6) . https://dx.doi.org/10.2174/187152711797247876
DOI https://dx.doi.org/10.2174/187152711797247876 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective
Current Gene Therapy Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Stem Cells and Bioactive Scaffolds as a Treatment for Traumatic Brain Injury
Current Stem Cell Research & Therapy Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Neuroprotective and Preventative Effects of Molecular Hydrogen
Current Pharmaceutical Design Olfactory Dysfunction and Cognitive Impairment in Age-Related Neurodegeneration: Prevalence Related to Patient Selection, Diagnostic Criteria and Therapeutic Treatment of Aged Clients Receiving Clinical Neurology and Community-Based Care
Current Clinical Pharmacology Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson’s Disease
Current Pharmaceutical Design Use of Deoxyribozymes for Gene Knockdown
Medicinal Chemistry Reviews - Online (Discontinued) Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis
Mini-Reviews in Medicinal Chemistry Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Structural and Molecular Basis of Carbohydrate-Protein Interaction Systems as Potential Therapeutic Targets
Current Pharmaceutical Design